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Abstract
Endothelin receptors (ETRs) are often overexpressed in ovarian tumors, which can be resistant to conventional
therapies. Thus, we investigated whether blockage of the ETR pathways using the dual ETR antagonist macitentan
combined with taxol or cisplatinum can produce therapy for orthotopically growing multidrug-resistant (MDR)
human ovarian carcinoma. In several studies, nude mice were injected in the peritoneal cavity with HeyA8-MDR
human ovarian cancer cells. Ten days later, mice were randomized to receive vehicle (saline), macitentan (oral,
daily), taxol (intraperitoneal, weekly), cisplatinum (intraperitoneal, weekly), macitentan plus taxol, or macitentan
plus cisplatinum. Moribund mice were killed, and tumors were collected, weighed, and prepared for immuno-
histochemical analysis. The HeyA8-MDR tumors did not respond to taxol, cisplatinum, or macitentan administered
as single agents. In contrast, combination therapy with macitentan and taxol or macitentan and cisplatinum sig-
nificantly decreased the tumor incidence and weight and significantly increased the survival of mice and their gen-
eral condition. Multiple immunohistochemical analyses revealed that treatment with macitentan and macitentan
plus taxol or cisplatinum inhibited the phosphorylation of ETRs, decreased the levels of pVEGFR2, pAkt, and
pMAPK in tumor cells after 2 weeks of treatment and induced a first wave of apoptosis in tumor-associated
endothelial cells followed by apoptosis in surrounding tumor cells. Our study shows that ovarian cancer cells,
which express the endothelin axis and are multidrug resistant, are exquisitely sensitive to treatment with a dual
ET antagonist and can be resensitized to both taxol and cisplatinum. This combined therapy led to a significant
reduction in tumor weight.
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Introduction
Ovarian cancer is the leading cause of mortality among women with
gynecologic cancers [1]. Whereas taxane- and cisplatinum-based
chemotherapies induce an initial favorable response in patients with
advanced ovarian cancer [2], the prognosis is grave owing to disease
recurrence and the emergence of drug-resistant disease [3]. Tumor cells
are genetically unstable, leading to biologic heterogeneity [4], which is
largely responsible for the emergence of multidrug-resistant (MDR)
cells that often express theMDR1 gene and its product, P-glycoprotein
(P-gp) [5]. The growth and spread of tumor cells in the body are de-
pendent on the continuous interaction of tumor cells with the organ
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microenvironment, which the tumor cells can exploit [4]. Targeting the
organ microenvironment in general and the tumor-associated vascular
system, in particular, is one approach to treating tumor cells, regardless
of their sensitivity or resistance to chemotherapeutic drugs [6,7].
An exciting approach for targeting tumor cells and the tumor vascu-
lature is through the endothelin (ET) pathway [7]. ETs are a family of
small peptides consisting (ET-1, -2, and -3) [8,9], which share struc-
tural homology and initiate signaling by binding to the G protein–
coupled receptors ETAR and ETBR [10]. ETs were classically defined
as potent vasoconstrictors, a role that led to considerable efforts to de-
velop nonpeptide ET receptor (ETR) antagonists to treat cardiovascular
diseases [11,12]. Further research, however, revealed that the ETs regu-
late diverse biologic processes such as tissue remodeling, tissue repair,
cellular differentiation [13], smooth muscle cell proliferation [14], and
inflammation [15]. Many tumors have been found to express ETs and
ETRs, and ET pathways have been shown to play important roles in
tumor cell proliferation, migration, and invasion and vascular differen-
tiation [16–19]. Activation of ETRs has been shown to play a role in
the inhibition of apoptosis, matrix remodeling, and bone deposition
in prostate cancer [20]. The ET axis has also been reported to be of
relevance in lung cancer [21], colon cancer [22], renal cancer [23],
cervical cancer [24], brain tumors [25], and ovarian cancer [26–28].
The role of the ETs and ETRs in the biology and therapy for ovarian
carcinoma has been described [29], and increased expression of ET-1
and ETAR on ovarian carcinoma cells and ETBR on intratumoral
vessels has been reported, as well as a relationship between the expres-
sion of ET-1 and vascular endothelial growth factor (VEGF) in the
development of ascites and resistance of cells to therapy [29].
We recently reported that the tissue-targeting ETR antagonist
macitentan (ACT-064992) [30] enhances the therapeutic efficacy of
paclitaxel against orthotopically implanted human ovarian carcinoma
by modulating the survival pathways of the tumor cells [7]. Because
the major cause of death from ovarian cancer is due to drug-resistant
tumor cells, we wished to determine whether macitentan is also effec-
tive in treating MDR ovarian cancer cells. Because all cells in the body
depend on an adequate supply of nutrients and oxygen for their sur-
vival, therapeutic regimens that target tumor-associated endothelial cells
can kill tumor cells regardless of their response to chemotherapeutic
drugs [31], and the induction of apoptosis in tumor-associated endo-
thelial cells has been shown to induce apoptosis in MDR prostate
cancer cells growing in the prostate of nude mice [6]. In the present
study, we determined whether the daily oral administration of the dual
ETR antagonist macitentan combined with once-weekly intraperitoneal
injection of taxol or cisplatinum can produce therapy for MDR human
ovarian tumors growing in the peritoneal cavity of nude mice.
Materials and Methods
Human Ovarian Cancer Cell Lines
The human ovarian cancer cell line HeyA8 and the MDR variant
HeyA8-MDR cell line were maintained as a monolayer culture in
Eagle minimal essential medium supplemented with 10% fetal bovine
serum (Life Technologies, Inc, Grand Island, NY ) as described
previously [7,32].
Reagents
Macitentan, also called ACT-064992 or N -(5-(4-bromophenyl)-
6-{2-(5-bromopyrimidin-2-yloxy)ethoxy}pyrimidin-4-yl)-N ′-
propylsulfamide, was provided by Actelion Pharmaceuticals, Ltd
(Allschwill, Switzerland) as powder. For oral administration, maciten-
tan was reconstituted in a 0.05% (wt/wt) methylcellulose solution
containing 0.05% (vol/vol) Tween 80 and diluted to different concen-
trations in 200 μl of vehicle before use. Taxol (taxol-injectable; Bristol-
Myers Squibb, Seattle, WA) and cisplatinum (APP Pharmaceuticals,
LLC, Schaumburg, IL) were diluted in distilled water for intraperito-
neal injections.
Animals
Female athymic nude mice (NCI-nu) were purchased from the
Animal Production Area of the National Cancer Institute – Frederick
Cancer Research Facility, Frederick, MD. Mice were housed and
maintained in specific pathogen-free conditions in facilities approved
by the American Association for Accreditation of Laboratory Animal
Care and in accordance with all current regulations and standards of
the US Department of Agriculture, the US Department of Health and
Human Services, and the National Institutes of Health. Mice were
used in these experiments in accordance with institutional guidelines
when they were 8 to 12 weeks old.
Rhodamine Efflux Assay in a Drug-Resistant Cell Line
HeyA8 and HeyA8-MDR cells were dissociated using cell dissocia-
tion buffer (Gibco, Rockville, MD) and incubated in Eagle minimal
essential medium with 10% fetal calf serum, 2 mM L-glutamine, 1%
nonessential amino acids, 1 mM sodium pyruvate, and penicillin/strep-
tomycin (Gibco) with the desired compounds (2 μM elacridar, 10 μM
macitentan, 10 μM ACT-132577 or dimethyl sulfoxide). After 30 min-
utes, 10 μMrhodamine 123 (R123; Invitrogen, Carlsbad, CA) was added
for 60 minutes at 37°C in 5% CO2. Subsequently, cells were washed
once with wash buffer (phosphate-buffered saline, 1% bovine serum
albumin, and 2 mM ethylenediaminetetraacetic acid) and resus-
pended in wash buffer, and intracellular rhodamine fluorescence
was determined.
Rhodamine fluorescence was measured on a FACS Canto II flow
cytometer (BD Biosciences, San Jose, CA) equipped with a 488-nm
argon laser and 530-nm band-pass filter. At least 10,000 events
were collected for all samples, and debris was eliminated by gating
on forward versus side scatter.
Orthotopic Implantation of Ovarian Cancer Cells
in Animal Models
To produce tumors, HeyA8-MDR cells were harvested from sub-
confluent cultures as described previously [7]. Cell viability was de-
termined by trypan blue exclusion, and only single-cell suspensions
of more than 95% viability were used for injection. The minimal
tumorigenic dose was determined to be 1 × 106 cells, and this number
of cells was used in all further experiments.
Therapy Experiments
In the first set of experiments, 1 × 106 HeyA8-MDR cells were
injected into the peritoneal cavity of female nude mice. Ten days later,
mice were randomized into treatment groups (n = 10/group) as fol-
lows: 1) daily oral administration and weekly intraperitoneal injection of
vehicle (control), 2) weekly intraperitoneal injection of taxol (5 mg/kg)
and daily oral administration of vehicle, 3) daily oral administration of
macitentan (50 mg/kg) and once-weekly intraperitoneal injection of
vehicle, 4) weekly intraperitoneal injection of taxol (5 mg/kg) and daily
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oral administration of macitentan (50 mg/kg), 5) weekly intraperitoneal
injection of taxol (5 mg/kg) and daily oral administration of macitentan
(10 mg/kg), and 6) weekly intraperitoneal injection of taxol (5 mg/kg)
and daily oral administration of macitentan (1 mg/kg).
In the second set of experiments, we determined the therapeutic
effect of macitentan combined with either taxol or cisplatinum against
the HeyA8-MDR peritoneal tumors. Ten days after intraperitoneal in-
jection of 1 × 106 cells, mice were randomized into 10 treatment groups
(n = 10/group) as follows: 1) daily oral administration and weekly
intraperitoneal injections of vehicle (control), 2) weekly intraperitoneal
injections of taxol (5 mg/kg) and daily oral administration of vehicle,
3) daily oral administration of macitentan (50 mg/kg) and weekly
intraperitoneal injections of vehicle, 4) daily oral administration of
macitentan (10 mg/kg) and weekly intraperitoneal injections of vehicle,
5) daily oral administration of macitentan (5 mg/kg) and weekly
intraperitoneal injections of vehicle, 6) daily oral administration of
macitentan (50 mg/kg) and weekly intraperitoneal injections of taxol
(5 mg/kg), 7) daily oral administration of macitentan (10 mg/kg)
and weekly intraperitoneal injections of taxol (5 mg/kg), 8) daily oral
administration of macitentan (5 mg/kg) and weekly intraperitoneal
injections of taxol (5 mg/kg), 9) weekly intraperitoneal injections of
cisplatinum (8 mg/kg) and daily oral administration of vehicle, and 10)
daily oral administration of macitentan (10 mg/kg) and weekly intra-
peritoneal injections of cisplatinum (8 mg/kg). The treatments contin-
ued until all control mice became moribund (8 weeks after injection
of tumor cells; 6 weeks of treatment). This allowed an evaluation of
10 mice per group.
To determine the sequence of microscopic changes in tumor cells
and tumor-associated endothelial cells, three additional mice from
each of the treatment groups were necropsied after 1, 2, or 3 weeks
of treatment. Tumors were prepared for histopathologic and immuno-
histochemical analyses.
Necropsy Procedures and Preparation of Tissues
Moribund mice or mice receiving 4 or 6 weeks of treatment were
killed by intramuscular injection of nembutal (1 mg/kg) and autop-
sied. The presence of tumors (tumor incidence) in the peritoneal cavity
and tumor weights were recorded. The tumor tissues were embedded
in OCT compound (Miles Inc, Elkhart, IN) and rapidly frozen in
liquid nitrogen or fixed in 10% buffered formalin for 24 hours and
processed to be embedded in a paraffin block.
Immunohistochemical Analyses and TUNEL Assay
The primary antibodies used in this study were goat anti-human ET-1
polyclonal antibody and goat anti-human ET-2 polyclonal antibody
(Santa Cruz Biotechnology, Inc, Santa Cruz, CA). HRP-conjugated
donkey anti-goat IgG (Santa Cruz Biotechnology, Inc) was used as the
secondary antibody. A TUNEL assay was performed using a commer-
cial apoptosis detection kit (Promega Corp, Madison, WI) with mod-
ifications as described previously [6,7]. For the color reaction of the
HRP-conjugated secondary antibodies, stable 3′,3-diaminobenzidine
(Research Genetics, Huntsville, AL) was used.
Immunof luorescence Staining
To measure the expression of ETAR, ETBR, phosphorylated
VEGFR2 (pVEGFR2), phosphorylated Akt (pAkt), and phosphory-
lated MAP kinase (pMAPK) in tumor cells and/or tumor-associated
endothelial cells, tissues were costained with the following pri-
mary antibodies: rat anti-mouse CD31 monoclonal antibody (BD
Pharmingen, San Diego, CA), goat anti-human ETAR polyclonal anti-
body (Santa Cruz Biotechnology, Inc), rabbit anti-ETAR antibody
(Acris Antibodies, Herford, Cambridge, United Kingdom), goat anti-
human ETBR polyclonal antibody (Santa Cruz Biotechnology, Inc),
rabbit anti-ETBR antibody (Acris), rabbit anti-mouse pAkt monoclonal
antibody (Cell Signaling Technology, Beverly, MA), rabbit anti-human
phosphorylated-p44/42 MAP kinase (Thr202/Thr204) polyclonal anti-
body (Cell Signaling Technology), rabbit anti-human pVEGFR2 mono-
clonal antibody (Cell Signaling Technology), and Ki-67 (sc-81514; Santa
Cruz Biotechnology, Inc). Goat anti-rat Alexa 594 IgG (Invitrogen),
rabbit anti-goat Alexa 488 IgG (Invitrogen), rabbit anti-goat fluorescein-
isothiocyanate IgG (Jackson Immuno Research Laboratories, West
Grove, PA), and goat anti-rabbit Alexa 488 IgG (Invitrogen) were pur-
chased for use as secondary antibodies [6,7].
Double Immunof luorescence Staining for ETRs and
Phosphoserine in Tumor Tissues
Because specific antibodies to detect activated, serine/threonine–
phosphorylated ETRs were not available, we used double immuno-
fluorescence staining with anti-ETAR or anti-ETBR antibodies and
anti-phosphoserine antibodies as previously described [7]. Anti-ETAR
(1:100; 12977; Abcam, Cambridge, MA), ETBR (1:100; 65972;
Abcam), and anti-phosphoserine (1:100; sc-81514; Santa Cruz Bio-
technology) were used as the primary antibodies, and Alexa Fluor
488 goat anti-mouse antibody (1:600; A11029; Invitrogen) was used
as the secondary antibody. Nuclei were stained with Hoechst 33342
dye (H3570; Invitrogen) [7].
Statistical Analyses
Tumor incidence, the incidence of ascites (χ2 test), tumor weight
(Mann-Whitney t test), and the number of Ki-67–positive and TUNEL-
positive cells (unpaired Student’s t test) were compared across the
treatment groups (SPSS program; SPSS Inc, Chicago, IL).
Results
Effects of Macitentan and Its Metabolite (ACT-132577)
on Rhodamine 123 Accumulation in HeyA8
and HeyA8-MDR Cells
P-gp, an efflux pump for many drugs, is highly expressed in HeyA8-
MDR cells but not in the parental HeyA8 cells [33]. We used P-gp–
mediated efflux of the fluorescent dye R123 as an indicator assay for
P-gp activity.We detected strong intracellular accumulation of R123 in
the parental HeyA8 cells (data not shown), indicating low drug efflux
activity. In contrast, in the absence of elacridar, a P-gp inhibitor, R123
did not accumulate within the HeyA8-MDR cells, indicating active
drug efflux. When elacridar was present, the intracellular R123 accu-
mulation was restored. Treatment with macitentan or with ACT-
132577, the major active metabolite of macitentan, did not lead to
intracellular accumulation of R123 inHeyA8-MDR, showing that these
compounds are not P-gp inhibitors. Macitentan and ACT-132577 were
tested at concentrations ranging from 10 nM to 50 μM, and none of
the drug concentrations were able to inhibit drug efflux.
Therapy for HeyA8-MDR Tumors with Macitentan and Taxol
In the first set of in vivo experiments, we determined whether
administration of taxol, macitentan, as well as macitentan and taxol
Translational Oncology Vol. 5, No. 1, 2012 Blockade of ETR for Therapy of MDR Ovarian Cancer Kim et al. 41
reduced the incidence and weight of HeyA8-MDR peritoneal tumors
(Table 1). As expected, taxol alone did not reduce the tumor incidence
or median weight of the tumors compared with the untreated control
group (median = 1.5 g, range = 1.0-2.2 g vs median = 1.4 g, range =
1.0-2.0 g; P > .05). Likewise, mice treated with macitentan alone
at 50 mg/kg had no decrease in tumor incidence or median tumor
weight (median = 1.6 g, range = 0.9-2.9 g vs median = 1.4 g, range =
1.0-2.0 g; P > .05). By contrast, mice treated with the combination of
taxol and 10 or 50mg/kgmacitentan, but not 1 mg/kg macitentan, had
significantly reduced tumor weights (median = 0.1 g, range = 0-0.6 g
and median = 0.5 g, range = 0-0.7 g, respectively, vs median = 1.4 g,
range = 1.0-2.0 g; P < .01). We did not observe any toxic effects (weight
loss) of the drugs in any of the above groups. The administration of
1 mg/kg macitentan plus taxol had no therapeutic effects. These data
clearly show that the daily oral administration of 10 mg/kg macitentan,
coupled with once-per-week 5 mg/kg taxol, significantly reduces the
weight (size) of HeyA8-MDR tumors.
In the next set of experiments, we repeated the macitentan and taxol
treatment and also studied whether the therapeutic effects could be
extended to another chemotherapeutic drug, cisplatinum (Table 2).
All control mice developed large peritoneal tumors and were necropsied
after 6 weeks of treatment (median = 4.5 g, range = 3.2-5.1 g). Treat-
ment with taxol alone (5 mg/kg), macitentan alone (5, 10, or 50 mg/kg),
or cisplatinum alone (8 mg/kg) produced no therapeutic benefits. Once
again, treatment of mice with a combination of taxol and either 10 or
50 mg/kg (but not 5 mg/kg) macitentan significantly reduced the me-
dian tumor weight (median = 1.4 g, range = 0-2.5 g and median =
1.5 g, range = 0-2.6 g, respectively, vs median = 4.5 g, range = 3.2-5.1 g;
P < .01). Furthermore, the combination of cisplatinum and 10 mg/kg
macitentan also significantly reduced the tumor weights (median =
1.4 g, range = 0-2.1 g vs median = 4.5 g, range = 3.2-5.1 g; P < .01).
Immunohistochemical Analyses of HeyA8-MDR Tumors
HeyA8-MDR cells growing in the peritoneal cavity of nude mice
were analyzed for expression of ET-1, ET-2, ETAR, and ETBR.
Similar to other human ovarian cancer cells, such as SKOV3ip1 and
IGROV1 [7], the HeyA8-MDR tumor cells express ET-1, ET-2,
ETAR, and ETBR (data not shown). Costaining for ETAR and ETBR
within the HeyA8-MDR tumors clearly demonstrates the heterogene-
ity of the expression of these two receptors. Some cells express ETAR,
some cells express ETBR, and many cells express both receptors (data
not shown).
Treatment with taxol alone had no effect on the phosphorylation
of VEGFR2, Akt, or MAPK (Figure 1). In contrast, treatment with
macitentan at 10 or 50 mg/kg (but not 1 mg/kg) alone or in combi-
nation with taxol significantly decreased the expression of pVEGFR2,
pAkt, and pMAPK in HeyA8-MDR cells. In addition, the combina-
tion of macitentan (at 10 or 50 mg/kg) and taxol produced a significant
increase in the number of apoptotic cells, as measured by TUNEL
staining (Figure 1).
In the last set of experiments, we used a colocalization assay to study
the macitentan-mediated inhibition of phosphorylation of ETAR
(Figure 2A) and ETBR (Figure 2B) in HeyA8-MDR tumors. Treat-
ment of mice with 10 or 50 mg/kg macitentan, with or without taxol
or cisplatinum, significantly inhibited the colocalization of serine phos-
phorylation and both ETR receptors, whereas treatment of mice with
only taxol or 5 mg/kg macitentan did not. Proteins phosphorylated on
serine but unrelated to the ETRs were still phosphorylated. Complete
Table 1. Treatment of HeyA8-MDR Human Ovarian Tumors Growing in the Peritoneal Cavity of Female Nude Mice with Macitentan and Taxol.
Treatment Group Body Weight (g), Mean ± SD Tumor Incidence Tumor Weight (g), Median (Range)
Control 25.7 ± 1.9 10/10 1.4 (1.0-2.0)
Macitentan, 50 mg/kg 25.3 ± 1.9 7/7 1.6 (0.9-2.9)
Taxol, 5 mg/kg 25.6 ± 2.6 10/10 1.5 (1.0-2.2)
Taxol + macitentan, 50 mg/kg 26.2 ± 2.0 5/10* 0.5 (0-0.7)†
Taxol + macitentan, 10 mg/kg 25.5 ± 2.8 7/10 0.1 (0-0.6)†
Taxol + macitentan, 1 mg/kg 25.6 ± 2.8 9/10 1.1 (0-1.8)
Mice were injected intraperitoneally with 1 × 106 HeyA8-MDR cells. Ten days later, treatment with vehicle, taxol, macitentan, or a combination of macitentan and taxol was initiated. Treatment
continued for 4 weeks, and the mice were necropsied. Tumor incidence and weight were recorded.
*Statistically significant compared with the control group, P < .05.
†Statistically significant compared with the control group, P < .01.
Table 2. Treatment of HeyA8-MDR Human Ovarian Tumors Growing in the Peritoneal Cavity of Female Nude Mice with Macitentan and Either Taxol or Cisplatinum.
Treatment Group Body Weight (g), Mean ± SD Tumor Incidence Tumor Weight (g), Median (Range)
Control 24.9 ± 2.6 10/10 4.5 (3.2-5.1)
Taxol, 5 mg/kg 24.1 ± 2.2 10/10 4.0 (2.9-5.2)
Macitentan, 50 mg/kg 25.6 ± 1.8 10/10 3.6 (2.9-4.8)
Macitentan, 10 mg/kg 23.6 ± 1.6 10/10 3.1 (2.2-4.6)
Macitentan, 5 mg/kg 25.4 ± 2.0 10/10 3.5 (2.5-5.3)
Macitentan, 50 mg/kg + taxol 26.0 ± 1.7 9/10 1.5 (0-2.6)*
Macitentan, 10 mg/kg + taxol 24.5 ± 2.3 8/10 1.4 (0-2.5)*
Macitentan, 5 mg/kg + taxol 23.1 ± 1.6 10/10 3.0 (2.0-5.0)
Cisplatinum, 8 mg/kg 19.6 ± 3.1 10/10 3.5 (2.5-4.2)
Macitentan, 10 mg/kg + cisplatinum 21.3 ± 3.2 8/10 1.4 (0-2.1)*
Mice were injected intraperitoneally with 1 × 106 HeyA8-MDR cells. Ten days later, treatment with vehicle, taxol, macitentan, and cisplatinum began and was continued until mice in the control group
became moribund (6 weeks). Tumor incidence and weight were recorded.
*Statistically significant compared with the control group, P < .01.
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inhibition of ETR phosphorylation was achieved 2 weeks after the
initiation of the treatment with 10 or 50 mg/kg macitentan (Figure 2,
A and B).
Proliferation and Apoptosis of HeyA8-MDR Cells
and Tumor-Associated Endothelial Cells
Treatment of mice with taxol, cisplatinum, or macitentan (5, 10, or
50 mg/kg) did not reduce the number of Ki-67–positive cells compared
with the controls (Figure 3). Combination therapy with macitentan
(10 or 50 mg/kg, but not 5 mg/kg) and taxol or macitentan (10 mg/kg)
and cisplatinum significantly reduced the number of proliferating
Ki-67–positive cells (mean ± SD = 32.6 ± 12.3, 31.6 ± 9.9, and
35.8 ± 8.9, respectively, vs 66.7 ± 19.5; P < .05).
Treatment of mice with taxol, cisplatinum, or macitentan (5, 10, or
50 mg/kg) alone did not increase the number of apoptotic tumor cells
or apoptotic tumor-associated endothelial cells (by TUNEL staining)
compared with control tumors. In contrast, treatment of peritoneal
HeyA8-MDR tumors with the combination of macitentan (10 or
50 mg/kg) and taxol significantly increased the number of apoptotic
cells compared with the control group (mean ± SD = 119.6 ± 32.7
and 125.0 ± 29.0, respectively, vs 7.4 ± 2.6; P < .01). The combi-
nation of macitentan (10 mg/kg) and cisplatinum also significantly
increased the number of TUNEL-positive cells compared with the
control group (mean ± SD = 120.8 ± 35.2 vs 7.4 ± 2.6; P < .01).
Time Course of Apoptosis Induction in HeyA8-MDR Tumor
Cells and Tumor-Associated Endothelial Cells
Tumor tissues were harvested after 1, 2, and 3 weeks of treatment
and analyzed by TUNEL and for colocalization of TUNEL with
CD31. One week after treatment, no apoptosis could be detected
in tumor cells and endothelial cells from mice treated with macitentan
either alone or in combination with taxol or cisplatin (Figure 4). By
the second week of treatment with macitentan (10 and 50 mg/kg but
not 5 mg/kg) and taxol, apoptosis was induced in the tumor-associated
endothelial cells and surrounding tumor cells. Three weeks after begin-
ning the combination treatments, apoptotic cells could be detected
all over the tumor and in endothelial cells (taxol plus macitentan, 10
and 50 mg/kg, but not 5 mg/kg). Likewise, treatment with 10 mg/kg
Figure 1. Immunohistochemical analyses of orthotopic HeyA8-MDR ovarian tumors. pVEGFR2, pAkt, pMAPK, and TUNEL-positive cells
are stained green. CD31-positive endothelial cells are stained red and endothelial cells positive for pAkt, pMAPK, and TUNEL are stained
yellow. Treatment with macitentan at 10 or 50 mg/kg (but not 1 mg/kg) alone or in combination with taxol inhibited phosphorylation of
VEGFR2, Akt, and MAPK. The combination of macitentan at 10 or 50 mg/kg and taxol induced apoptosis in tumor-associated endothelial
cells (yellow) and tumor cells (green).
Translational Oncology Vol. 5, No. 1, 2012 Blockade of ETR for Therapy of MDR Ovarian Cancer Kim et al. 43
Figure 2. Double immunofluorescence staining for phosphorylated ETRs. HeyA8-MDR tumor sections were stained with an anti-
phosphoserine antibody (red), (A) anti-ETAR antibody (green), or (B) ETBR antibody; the phosphorylated receptors are stained yellow. Treat-
ment with macitentan at 10 or 50 mg/kg (but not 5 mg/kg), administered alone or with taxol, inhibited phosphorylation of ETAR and ETBR.
Macitentan (10 mg/kg) plus cisplatinum also inhibited the phosphorylation of the receptors. Therapeutic effective inhibition of receptor
phosphorylation was achieved after 2 weeks of treatment.
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macitentan and cisplatinum induced apoptosis of tumor-associated
endothelial cells and surrounding tumor cells 3 weeks after the initia-
tion of treatment (Figure 4).
Discussion
Development of resistance to platinum compounds and taxanes, the
most effective treatments used in ovarian cancer today, is based on many
but different molecular mechanisms [34]. In the present study, we used
the MDR ovarian cancer cell line HeyA8-MDR as a representative
model for MDR ovarian cancer. The resistant cell line was generated
by in vitro exposure to increasing levels of taxol [32]. HeyA8-MDR cells
overexpress P-gp and show a higher level of taxol efflux than the parental
cell line [33], making them highly resistant to taxol. Furthermore,
HeyA8-MDR human ovarian cancer cells growing in the peritoneal
cavity of female nude mice were resistant to systemic administration
of taxol or cisplatinum. Our results show that the observed resensitiza-
tion of the tumors to chemotherapy by macitentan is unlikely to be due
to efflux pump inhibition.
The low responsiveness to cisplatinum must be associated with
orthotopic growth in vivo because the cells are platinum-sensitive
in vitro. The cisplatinum dose used led to weight loss in animals
(Table 2) and was therefore a biologically active, maximally tolerated
dose. In vivo, many mechanisms leading to resistance to platinum
drugs have been described, ranging from impaired drug delivery to
the up-regulation of survival pathways [35]. Of relevance to ETRs
and GPCRs, it has been recently shown that chemoresistance to both
taxanes and platinum compounds in ovarian cancer cells, including
HeyA8-MDR, can be associated with the amplification of survival
pathways by the down-regulation of regulators of G protein signaling
(RGS) proteins, which activate GPCR signaling [36]. Therefore,
antagonizing G protein receptor signaling, such as ET/ETR signaling,
may resensitize cells to chemotherapeutics in vivo. In this context, it
is interesting to note that the minimal effective macitentan dosage
in models of chemosensitive ovarian tumors was determined to be
30 mg/kg daily, whereas HeyA8-MDR tumors could be resensitized
to chemotherapy, including expression of biomarkers with a dosage
of 10 mg/kg daily.
ETs also play important roles in cell survival and apoptosis. A recent
work suggests that ET-1 is necessary for the survival of lung fibroblasts
and rapidly activates numerous critical survival pathways in vitro,
including the phosphatidylinositol 3-kinase/Akt and p38 MAPK path-
ways [37]. These downstream pathways are also thought to be important
for regulating tumor cell survival as well. ET-1 acts as a survival factor for
both colon and ovarian cancer cells by inhibiting chemotherapy-induced
apoptosis through activation of the phosphatidylinositol 3-kinase/Akt
pathway [38,39]. Indeed, the ET signaling axis can provide protective
effects against chemotherapy in vivo. For example, mice treated with a
pharmacologic ETAR inhibitor in combination with docetaxel had sig-
nificantly smaller pancreatic tumor burdens and growth rates, compared
with those treated with vehicle alone [40].
Systemic administration of macitentan (as a single agent or com-
bined with chemotherapy) did not affect the expression ETs and ETRs
but inhibited the phosphorylation of the ETRs as well as the Akt,
MAPK, and VEGFR2 pathways [7]. Thus, inhibition of cell survival
pathways may be another mechanism by which macitentan sensitizes
tumor cells to chemotherapy.
Our data with macitentan confirm the antitumor effect of ETR
antagonists using macitentan in combination with chemotherapy.
In contrast to other ETAs, zibotentan, and ABT-627, which showed
significant antitumor effects as single agents [19,33], macitentan alone
decreased the expression of survival pathways but was ineffective or
was only marginally effective alone as an antitumor agent, therefore
leading to strong synergism with chemotherapy.
Figure 3. Inhibition of cell proliferation in orthotopic HeyA8-MDR tumors. Nuclei 4′,6-diamidino-2-phenylindole, dihydrochloride are
stained dark blue and Ki-67–positive tumor cells are green, dark blue, and green, yielding a sky blue color for dividing cells. CD31-positive
vessels are stained red, and dividing endothelial cells are white (red and green results in white color, arrows). Note the significant
decrease in the number of Ki-67–positive cells in tumor and endothelial cells (arrows) in tumors of mice treated with taxol and macitentan
(10 or 50 mg/kg), as well as those treated with macitentan (10 mg/kg) and cisplatinum.
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Regardless of the sensitivity to chemotherapeutic drugs, the survival
of all cells depends on a viable vasculature [41]. Specifically, 2 weeks
after the initiation of treatment with macitentan and taxol, and 3 weeks
after the initiation of treatment with macitentan and cisplatinum, the
first wave of apoptosis in the HeyA8-MDR tumors was detected in
tumor-associated endothelial cells, which led to subsequent apoptosis
in the surrounding tumor cells that depend on the tumor-associated
blood vessels for oxygen and nutrients [6]. The reason for the slower
induction of apoptosis in tumor-associated endothelial cells by the
macitentan-cisplatinum combination needs further investigation, but
induction of apoptosis in tumor-associated endothelial cells was a com-
mon denominator. Because inhibition of phosphorylation of ETR,
Akt,MAPK, and VEGFR2was correlated with therapeutic efficacy, they
may be used as biologic markers in the follow-up biopsies in possible
clinical studies to determine an effective dose and schedule. HeyA8-
MDR cells do not produce peritoneal ascites, but VEGFR2 in tumor
cells and tumor-associated endothelial cells was phosphorylated, and
treatment with macitentan inhibited its phosphorylation. Thus, the
function of VEGFR in HeyA8-MDR cells may be related to the survival
and migration of endothelial cells rather than vascular permeability.
In summary, several mechanisms can lead to drug resistance in vivo,
and macitentan is able to resensitize tumors expressing the ET axis to
chemotherapy. Modulation of survival and proliferation pathways by
macitentan, as demonstrated by a reduction in phosphorylated ETRs
and cell signaling phosphoproteins in tumor-associated endothelial
cells and MDR cancer cells render them highly sensitive to taxol or
cisplatinum. Macitentan combined with chemotherapeutic drugs
induces apoptosis in tumor-associated endothelial cells followed by
apoptosis of cancer cells after 2 weeks of therapy, regardless of the
mechanism of therapy resistance. Thus, targeting ETR with macitentan,
a dual tissue-targeting ETR antagonist, in combination with chemo-
therapy, offers an attractive new modality to treat MDR ovarian tumors.
Macitentan targets not only cancer cells but also tumor-associated endo-
thelial cells that might sensitize tumors to chemotherapy irrespective of
the drug resistance mechanism.
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